Jeff Weisel has more than 20 years experience working with leading life sciences and healthcare organizations on issues of strategic change and business innovation, with focus on Asia-Pacific. He currently provides strategic and transaction advisory for sector clients with EY. Jeff has lived in Asia since 1994 and is based in Singapore.
Previously, Jeff was the Market Access & Policy Director for Asia, Australia, Africa, Middle East for AbbVie (including as Abbott) where he developed and led the company’s engagement with governments, payers, large account purchasers and other stakeholders and served on the Global Market Access Council. He also contributed to overall industry development as a member of the PhRMA Asia Senior Executives Committee. Before that he led Novartis in major Asia Pacific growth initiatives in business development and licensing, key account management, market access and strategic planning that added significant increases in regional revenue and established several globally recognized best practices. In these leadership roles, he helped deliver the regional success of top global brands such as Humira, Lucentis and Diovan.
Prior to joining Novartis, Jeff spent seven years with IBM and PwC where he led the life sciences consulting practice in Asia working with global and local market leaders, start-up companies and government organizations in pharmaceuticals, biotech, vaccines, diagnostics, medical devices, healthcare services and health insurance.
Jeff has served on the Board of Governors and as chair of the Healthcare Committee for the American Chamber of Commerce in Singapore. He is also currently a lecturer on market access strategy at the ESSEC Business School and a member of the Singapore National Health Innovation Center’s expert panel on new medical technologies.
He holds an M.A in Asian Studies and Economics from George Washington University and a B.A. in Political Science from Boston University.